A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...
OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative ...
A phase Ib/II trial testing famitinib added to dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results